Christof Scheid
A5019564821- Multiple Myeloma Research and Treatments
- Hematopoietic Stem Cell Transplantation
- Protein Degradation and Inhibitors
- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Cancer Treatment and Pharmacology
- Chronic Lymphocytic Leukemia Research
- Acute Lymphoblastic Leukemia research
- CAR-T cell therapy research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Lymphoma Diagnosis and Treatment
- Peptidase Inhibition and Analysis
- Neutropenia and Cancer Infections
- Immune Cell Function and Interaction
- Renal Transplantation Outcomes and Treatments
- Eosinophilic Disorders and Syndromes
- T-cell and B-cell Immunology
- Polyomavirus and related diseases
- Cancer therapeutics and mechanisms
- Ocular Surface and Contact Lens
- Cytomegalovirus and herpesvirus research
- Immunotherapy and Immune Responses
- Corneal Surgery and Treatments
- Viral-associated cancers and disorders
- Monoclonal and Polyclonal Antibodies Research
University of Cologne
2016-2025
University Hospital Cologne
2016-2025
Heinrich Heine University Düsseldorf
2005-2025
Düsseldorf University Hospital
2019-2025
Centrum für Integrierte Onkologie
2015-2024
University Clinical Centre
2023
Integrated Oncology (United States)
2022
John Wiley & Sons (United States)
2018-2021
Hudson Institute
2018-2021
Cologne Excellence Cluster on Cellular Stress Responses in Aging Associated Diseases
2015-2019
We investigated whether bortezomib during induction and maintenance improves survival in newly diagnosed multiple myeloma (MM).In all, 827 eligible patients with symptomatic MM were randomly assigned to receive therapy vincristine, doxorubicin, dexamethasone (VAD) or bortezomib, (PAD) followed by high-dose melphalan autologous stem-cell transplantation. Maintenance consisted of thalidomide 50 mg once per day 1.3 mg/m(2) every 2 weeks for years. The primary analysis was progression-free (PFS)...
Chronic myeloid leukemia (CML)-study IV was designed to explore whether treatment with imatinib (IM) at 400 mg/day (n=400) could be optimized by doubling the dose (n=420), adding interferon (IFN) (n=430) or cytarabine (n=158) using IM after IFN-failure (n=128). From July 2002 March 2012, 1551 newly diagnosed patients in chronic phase were randomized into a 5-arm study. The study powered detect survival difference of 5% 5 years. After median observation time 9.5 years, 10-year overall 82%,...
Disruption of intestinal microbial communities appears to underlie many human illnesses, but the mechanisms that promote this dysbiosis and its adverse consequences are poorly understood. In patients who received allogeneic hematopoietic cell transplantation (allo-HCT), we describe a high incidence enterococcal expansion, which was associated with graft-versus-host disease (GVHD) mortality. We found
Purpose To compare a reduced-intensity conditioning regimen (RIC) with myeloablative (MAC) before allogeneic transplantation in patients myelodysplastic syndrome (MDS) within randomized trial. Patients and Methods Within the European Society of Blood Marrow Transplantation, we conducted prospective, multicenter, open-label, phase III trial that compared busulfan-based RIC MAC MDS or secondary acute myeloid leukemia. A total 129 were enrolled from 18 centers. randomly assigned 1:1 ratio...
Despite treatment advances, patients with multiple myeloma (MM) often progress through standard drug classes including proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), and anti-CD38 monoclonal antibodies (mAbs). LocoMMotion (ClinicalTrials.gov identifier: NCT04035226) is the first prospective study of real-life care (SOC) in triple-class exposed (received at least a PI, IMiD, mAb) relapsed/refractory MM (RRMM). Patients (N = 248; ECOG performance status 0-1, ≥3 prior lines...
The GMMG-CONCEPT trial investigated isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in transplant-eligible (TE) transplant-noneligible (TNE) patients with newly diagnosed multiple myeloma (NDMM) exclusively high-risk disease for whom prospective trials are limited, aiming to induce minimal residual (MRD) negativity.This academic, investigator-initiated, multicenter, phase II enrolled NDMM (HRNDMM) defined by mandatory International Staging System stage II/III combined...
To evaluate the role of a second allogeneic hematopoietic stem-cell transplantation (HSCT2) given for relapsed acute leukemia (AL) after related or unrelated first (HSCT1) and to analyze donor change HSCT2 in both settings.We performed retrospective registry study on 179 HSCT2s relapse HSCT1 from matched donors (n = 75) 104), using identical alternative HSCT2. Separate analyses were according at HSCT1.Independent donor, 74% patients achieved complete remission HSCT2, half these experienced...
Purpose To compare the outcome of patients with Hodgkin lymphoma who received post-transplantation cyclophosphamide-based haploidentical (HAPLO) allogeneic hematopoietic cell transplantation conventional HLA-matched sibling donor (SIB) and unrelated (MUD). Patients Methods We retrospectively evaluated 709 adult were registered in European Society for Blood Marrow Transplantation database HAPLO (n = 98), SIB 338), or MUD 273) transplantation. Results Median follow-up survivors was 29 months....
In the prospective phase 3 HOVON-50/GMMG-HD3 trial, patients randomized to TAD (thalidomide, doxorubicin, dexamethasone) had a significantly higher response rate (at least PR) after induction compared with VAD (vincristine, adriamycin, dexamethasone, 72% vs. 54%, p
Broadly neutralizing antibodies (bNAbs) represent a promising approach to prevent and treat HIV-1 infection. However, viral escape through mutation of the envelope glycoprotein (Env) limits clinical applications. Here we describe 1-18, new VH1-46-encoded CD4 binding site (CD4bs) bNAb with outstanding breadth (97%) potency (GeoMean IC50 = 0.048 μg/mL). Notably, 1-18 is not susceptible typical CD4bs mutations effectively overcomes resistance other bNAbs. Moreover, mutational antigenic...
In contrast to 5-azacytidine (5-aza), allogeneic stem-cell transplantation (HSCT) represents a curative treatment strategy for patients with myelodysplastic syndromes (MDS), but therapy-related mortality (TRM) limits its broader use in elderly MDS. The present prospective multicenter study compared HSCT following 5-aza pretreatment continuous higher-risk MDS age 55-70 years. One hundred ninety median of 63 years were enrolled. Patients received 4-6 cycles followed by HLA-compatible after...
Abstract The phase III study was designed to compare event‐free survival (EFS) after treosulfan‐based conditioning with a widely applied reduced‐intensity (RIC) busulfan regimen in older or comorbid patients acute myeloid leukemia (AML) myelodysplastic syndrome (MDS) undergoing allogeneic hematopoietic cell transplantation (HCT). A previously reported confirmatory interim analysis of the randomized clinical including 476 demonstrated statistically significant noninferiority for treosulfan...